Monday, 29 May 2017

Global MicroRNA Tools Market Share by Industry Research 2016 - 2023

MicroRNA, referred as miRNA is a class of naturally occurring, small non-coding RNA molecule, which is found in plants, some of the viruses and animals. Over the past decade, it has become gradually clearer that it plays an important role in the regulation of gene. Within 10 years of research has evolved from discovering the presence of miRNA in mammals to their therapeutic applications in several diseases. Inherent to the fast developments and overall excitement surrounding miRNA findings is the rising need for applicable and validated experimental tools to allow the researchers to elucidate the expression and biological function of miRNA. It presents a fast growing research area with vast probability to discover the novel and exciting mechanism related to physiology and pathology. Technological developments such as bioinformatics and next generation sequencing (NGS) permitted the identification of excessive number of additional putative miRNA in different organisms in current years.


The vital first step in miRNA research is detection of miRNA, governed by many regulatory checkpoints. Though it is hard to estimate the whole number of miRNA, to date, over 2000 human, miRNA are recognized and deposited in miRBase. The process of identifying miRNA is still challenging and complex and needs an interdisciplinary strategies and it should have integrational experimental approached with computational methods. Scientist can now use the advanced tools to resolve the complex findings of miRNA research.

The miRNA tools market is segmented into tools, end users and geography. The tools classified as microarrays, next generation sequencing (NGS), quantitative real time PCR (qRT-PCR), northern blotting, in situ hybridization (ISH). The Quantitative real time PCR (qRT-PCR) is known to be the largest and fastest growing segment in this market. The end users covered are biotech companies, academic and research institutes. Based on the geography, miRNA market segmentation is North America, Europe Asia Pacific, Latin America, and Middle East and Africa. United States reported to have the largest share in miRNA market followed by Europe. Due to the increased investment by foreign countries in China and India expected to be the fastest growing countries in the miRNA research tools market

The miRNA research, driven by its therapeutic and diagnostic potential has fueled the growth of global miRNA tools market. The recent developments in the molecular biology and genomic technologies will uplift the market. Moreover higher research funding, increased outsourcing to contract research in developed countries and increased investments by the foreign countries in the developing nation such as China, India etc. will create an opportunity and drive the miRNA tools market. High cost involved in the manufacturing of research tools and the lack of experienced professionals will be responsible to restrain the growth of the market.

Some of the major players in the microRNA research tools market are Affymetrix, Agilent Technologies, Exiqon A/S, Illuminia, Life Technologies Corporation, Phalanx Biotech Group, Qiagen NV, Roche Holding AG and Thermo Fisher Scientific Inc.

Fill the form for an exclusive sample of this report @
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=11111

About Us    

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Wednesday, 24 May 2017

Global Over-the-Counter Drugs Market Trends & Industry Forecast by 2016 - 2024

Over-the-counter drugs, also known as non-prescription drugs, refer to medicines that can be bought without a prescription. These drugs are safe and effective when a consumer follows the directions on the label or as provided by a physician. Over-the-counter (OTC) drugs are primarily used to treat conditions that do not require direct consultation of a doctor. OTC drugs are safe and well tolerated. These provide affordable treatment and also help to decrease the workload of physicians. The OTC drugs helps to build a diverse product portfolio for health care business of pharmaceutical companies also it helps to extend product range for consumer brands of consumer goods companies. OTC drugs are easily available in pharmacies. Hence, some of these drugs have restrictions in the U.S. This restricted class of drugs include emergency contraception, pseudoephedrine, and some Schedule V controlled drugs. These products are considered OTC; however, these are not directly kept on pharmacy counters and must be dispensed by a pharmacist after confirming age, identity, and patient knowledge regarding usage of product. 


The global over-the-counter drugs market has been segmented based on product type and geography. Based on product type, the market has been categorized into analgesics & pain relievers, cough, cold and flu products, dermatological products, vitamin supplements, mineral supplements, gastrointestinal products, sleep aids, weight loss products, smoking cession aids, ophthalmic products, and other products. Analgesics & pain relives, cough, cold and flu products, dermatological products, vitamin supplements, and mineral supplements are the major market segment. Among all major segments analgesics & pain relives hold the maximum market share. Weight loss products and smoking cession aids are likely to witness high growth in the next few years due to increase in awareness about healthy lifestyle.

Geographically, the over-the-counter drugs market has been segmented into five major regions: North America (U.S. and Canada), Europe (Germany, France, U.K., etc.), Asia Pacific (Australia, China, Japan, India, etc.), Latin America, and Middle East & Africa. North America is the leading market for OTC drugs in terms of revenue, followed by Europe. Asia Pacific and Latin America are emerging markets, which are expected to witness strong growth during the forecast period from 2016 to 2014. The strong growth is anticipated due to increase in healthcare industries and increase in the investment of government to develop health care industries. The over-the-counter drugs market in countries such as China, India, and Brazil are projected to expand at high growth rate during the forecast period due to increase in awareness among the population about usage of over-the-counter drugs to treat minor health issues.

Other factors that drive the over-the-counter drugs market are changes in cultural attitudes regarding self-medications required for minor health problems, convenience of direct purchase, affordability of over-the-counter drugs, high adoption and acceptance in developing markets, savings enabled by the usage of over the counter drugs, and innovations and developments in drugs. The market is also experiencing certain restraints such as stiff competition among the existing players, high possibilities of substance abuse and addiction, complications and severity involved in taking wrong medications due to misdiagnosis or incorrect self-diagnosis, and lack of awareness among the rural population in developing and underdeveloped economies.

Major players operating in the OTC market include Alkem Laboratories Limited, Bayer AG, Boehringer Ingelheim GmbH, Cipla, Inc., GlaxoSmithKline Plc., Glenmark Pharmaceuticals Limited, Johnson & Johnson Services, Inc., Merck KGaA, Novartis AG, Pfizer, Inc., Sanofi, Teva Pharmaceutical Industries Ltd., and Sun Pharmaceutical Industries Ltd.

The report offers a comprehensive evaluation of the market. It does so via in-depth insights, understanding market evolution by tracking historical developments, and analyzing the present scenario and future projections based on optimistic and likely scenarios. Each research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology developments, types, applications, and the competitive landscape. 

Fill the form for an exclusive sample of this report @
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=14117

About Us    

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Global Viral Hemorrhagic Fever Market Key Trends & Industry Forecast 2016 - 2024

Viral Hemorrhagic Fever Market: Overview

Viral hemorrhagic fever is referred to as severe multisystem (multiple organs) syndrome in our body that is affected by certain viruses. Viral hemorrhagic fever can be described as a group of illness caused by four families of RNA viruses namely arenaviruses, filoviruses, bunyaviruses and flaviviruses. Due to hemorrhagic fever, the overall vascular system in our body gets damaged and the body loses its ability to regulate. Hemorrhagic fever is rarely life threatening but sometimes it leads to emergency medical conditions. The Centers for Disease Control and Prevention (CDC) has stated that the natural reservoir (host) for the causative organism of hemorrhagic fever is an animal or insect, but humans are infected when they come into contact with infected hosts.


It has also stated that most of the viruses associated with viral hemorrhagic fever are considered as zoonotic (animal host). Few animals which act as a host for hemorrhagic fever includes rat, cotton rat, deer mouse, house mouse, and other field rodents. Few examples of viral hemorrhagic fever include ebola, marburg, dengue, lassa and yellow fever. Possible signs and symptoms of viral hemorrhagic fever include fatigue, muscle pain, bone or joint aches, high fever and dizziness. Other signs and symptoms considered as life threatening includes shock, nervous system malfunctions, coma, delirium, kidney failure and liver failure.

Risk factor for viral hemorrhagic fever includes slaughtering infected animals, working with the sick, sharing needles to use intravenous drugs, having unprotected sex and working outdoors or in rat-infected buildings. Possible complication associated with viral hemorrhagic fever includes brain damage, heart failure, kidney damage and malfunctioning of the liver. Presently, there is no specific diagnosis and proper treatment option is available in the market to treat viral hemorrhagic fever.

Viral Hemorrhagic Fever Market: Growth Enablers

Increasing unhygienic lifestyle among population is considered as a major market driving factor for the global viral hemorrhagic fever treatment market because animal that resides close contact with human are act as host for the viruses. Moreover, increasing awareness among people about hemorrhagic fever would further accentuate the market growth in few of the developed nations in the world.

Since, currently no treatment option has been made available in the market for hemorrhagic fever, the virus has the potential to being utilize as bio-warfare. The above mentioned factor is considered as a significant ethical issue worldwide. However, the low awareness about viral hemorrhagic fever in a few of the developing nations is considered as a factor that might restrict its demand in the global viral hemorrhagic fever treatment market.

Viral Hemorrhagic Fever Market: Region-wise Insight

North America and Europe dominate the global market for viral hemorrhagic fever treatment due to increasing awareness among people and high prevalence rate of viral hemorrhagic fever in these regions. Moreover, initiatives taken by the federal government also help the market growth in North American and European regions.

Asia-Pacific is considered as an untapped market due to lack of proper healthcare facilities in few Asian countries. Asian market growth will be fuelled by the presence of untapped opportunities due to extensive increase in the healthcare infrastructure (healthcare cost, healthcare facility and healthcare budget). Rest of the world (RoW) holds fourth position in the global viral hemorrhagic fever treatment market due to poor economic and health condition in most of the African countries.

The report offers a comprehensive evaluation of the market. It does so via in-depth insights, understanding market evolution by tracking historical developments, and analyzing the present scenario and future projections based on optimistic and likely scenarios. Each research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology developments, types, applications, and the competitive landscape. 

Fill the form for an exclusive sample of this report @
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=13619

About Us    

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Glaucoma Therapeutics Market is Registering a Healthy 3.40% CAGR between 2016 and 2024

Glaucoma Therapeutics Market: Overview 

Glaucoma is an ocular disease which affects the optic nerve of the iris and progression of the same results into vision loss and blindness. The treatment for glaucoma starts with topical eye drops belonging to the class of prostaglandins, beta blockers, alpha agonist, combined medication, carbonic anhydrase inhibitor and cholinergic. Administration of these eye drops reduces the production of the fluid inside eyes thereby reducing the intraocular pressure. Using topical eye drops is an alternative for surgery or delays the surgical procedure. This report analyzes the current and future prospects of the glaucoma therapeutics market based on type of drug class, end user and geography.


Glaucoma Therapeutics Market: Scope and Methodology

The research is a combination of primary and secondary research, conducted for understanding and arriving at trends, used to forecast the expected revenue of the major glaucoma therapeutics market in the near future. Primary research formed the bulk of our research efforts with information collected from in-depth interviews and discussions with a number of key industry experts and opinion leaders. Secondary research involved study of company websites, annual reports, press releases, investor presentations, analyst presentation and various international and national databases. The report provides estimated market size in terms of US$ Mn for each by drug class, end user, and geography for the period 2014 to 2024, considering the macro and micro environmental factors. The revenue generated from each product was calculated by considering number of products used in the procedures and their market demand as per their use, number of product launched, average cost of products of each sub segment, trends in industry, end user trend, and adoption rate across all the geographies. The revenue generated for drug class was calculated on the basis of prevalence of diseases, and number of people affected by the disease

The market report comprises an elaborated executive summary, which includes market snapshot that provides information about various segments of the market. It also provides information and data analysis of the market with respect to market segments based on drug class, end-user, and geography. The market overview section of the report analyzes market dynamics such as drivers, restraints and opportunities that influences the glaucoma therapeutics market in the current and future scenario.

Based on geography, the market has been analyzed for major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. The study also covers detailed country analysis contributing majorly in the glaucoma therapeutics market.

Glaucoma Therapeutics Market: Competitive Landscape

Market share analysis among the market players is analyzed to signify the contribution of these players in the market in terms of percentage share. All these factors will help the market players to decide about the business strategies and plans to strengthen their positions in the global market. The report also profiles the major players in the market and provides various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major companies profiled in the glaucoma therapeutics market are Allergan Inc., Merck & Co., Pfizer Inc., Novartis AG., Santen Pharmaceuticals, Valeant Pharmaceuticals and Aerie Pharmaceuticals.

Fill the form for an exclusive sample of this report @
http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=16406

About Us    

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Global Outlook for Bovine Respiratory Disease Treatment Market By Key Trends and Analysis 2024

Global Bovine Respiratory Disease Treatment Market: Overview

Bovine respiratory disease (BRD) is a multifactorial and complex disorder caused due to combination of more than one microbial pathogens, impaired host immunity, inadequate housing conditions, and environmental factors. The major factor leading to bovine respiratory diseases are host factors, environmental factors, and direct influence of infectious agents such as virus, bacteria, and parasites. However, due to increasing consumption of milk and beef products, the need for bovine respiratory disease treatment has increased across the globe.

Moreover, according to the World Bank Group (2016), global human population is estimated to be 7.4 billion in 2016 and is growing at a rate of 1.8% per year. Hence, demand for beef has increased due to rising population and increasing disposable income across the world. The rising demand for high quality bovine derived products is influencing the bovine respiratory disease treatment market. Despite of innovations in veterinary medicines and advancement in technology, bovine respiratory disease is the leading cause to impact negatively on both the dairy and beef industries due to calf mortality, additional labor cost and treatment expenses. Moreover, bovine respiratory disease affects adversely on reproductive performance, growth and longevity of cattle. Hence, prevention and treatment of bovine respiratory disease have become important to decrease the impact on animal production and the beef industry. Therefore, the bovine respiratory disease treatment market is anticipated to witness significant growth in terms of revenue during the forecast period.


Global Bovine Respiratory Disease Treatment Market: Segmentation

In terms of treatment type, the bovine respiratory disease treatment market has been categorized into vaccines, antibiotics, NSAIDs, and immunomodulators. Causative agents such as viruses leading to bovine respiratory disease have no direct treatment. Hence, vaccination is the preferred choice of preventive action against the disease. This increase market potential for vaccines. However, virus infected cattle is exposed to bacteria, parasites, and various other factors. Therefore, antibiotics are the preferred choice of treatment for bovine respiratory diseases. Effective treatment and significant demand has increased the scope for antibiotics in the bovine respiratory disease treatment market.

However, according to NCBI report, combination treatment with anti-inflammatory drugs such as NSAIDs has better results over the monotherapy of antibiotics. This has led to increase in usage of NSAIDs in bovine respiratory disease treatment. Bovine respiratory disease is generally treated with several combination therapies. However, growing resistance to antibiotics and drying pipeline has increased demand for novel treatment options for which cattle do not develop resistance, and consequently there is no impact on human life.

Development of newer generation antibiotics for cattle is anticipated to drive the global bovine respiratory disease treatment market during the forecast period. In order to avoid the issue of antibiotics resistance in bovine population, preventive measures such as vaccination and immunomodulators has observed increased global acceptance against the bovine respiratory disease. Hence, preventive treatment is gaining momentum due to growing awareness about the negative impact of antibiotics on human health. This has driven the market for immunomodulators, vitamin injections, and other immunity building products.

In terms of disease type, the market has been segmented into upper respiratory tract infections, diphtheria, and pneumonia (lower respiratory tract infection). Upper respiratory tract infections dominated the global bovine respiratory disease market, accounting for significant share in terms of revenue in 2015. Respiratory infections first affect the upper respiratory tract, which is also the most vulnerable region, followed by other parts of the respiratory tract. Diphtheria accounted for significant share of the bovine respiratory disease treatment market in 2015. Pneumonia (lower respiratory tract infection) accounted for high market share, followed after upper respiratory tract infection in 2015. Hence, early detection of infection is important in bovine respiratory diseases treatment.

In terms of distribution channel, the global bovine respiratory disease treatment market has been segmented into veterinary hospitals, veterinary clinics, private veterinary pharmacies, and veterinary research institutes. Veterinary hospitals dominated the global bovine respiratory disease market in 2015. The segment dominated the market due to factors such as rising population of cattle which increases prevalence of bovine respiratory diseases. The private veterinary pharmacies distribution channel segment is projected to register significant CAGR during the forecast period. The segment is likely to witness strong growth in most of the emerging parts of the world and preference for medicines from private veterinary pharmacies for bovine serum respiratory diseases. However, the veterinary clinics and veterinary research institutes segments are expected to grow steadily as majority of procedures are carried out in veterinary hospitals.

Global Bovine Respiratory Disease Treatment Market: Geographical and Competitive Dynamics

Geographically, the bovine respiratory disease treatment market has been categorized in five major regions: North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. North America held the major share of the global bovine respiratory disease treatment market in 2015, where the U.S. dominates the market in terms of revenue. Europe accounted for a significant share of the market in 2015. Changing environmental factors, growing prevalence of causative agents for respiratory disease, increasing demand for quality bovine products, and rising bovine population are the key factors driving the bovine respiratory disease treatment market in Europe. Asia Pacific is the largest producer of bovine livestock. Hence, it presents significant opportunities in the bovine respiratory disease treatment market. India and China are the key markets for bovine respiratory disease treatment, as these have largest livestock population compared to other countries across the globe. Latin America and Middle East & Africa have comparatively smaller markets for bovine respiratory disease treatment. However, Brazil, Mexico, and Argentina are the emerging markets in Latin America due to significant number of livestock population.

Key players operating in the global bovine respiratory disease treatment market are Merck & Co., Inc., Zoetis Services LLC, Bayer AG, Elanco, Merial, Boehringer Ingelheim GmbH, Virbac Group, Ceva, Vetoquinol, and Bimeda Animal Health, among others.

Fill the form for an exclusive sample of this report @
http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=13700

About Us    

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.